Ticker Symbol: TARA
Protara Therapeutics Inc
$7.27 - 20-12-2024 4 p.m. ET
Exchange: NASDAQ
Country:
US
Currency:
USD
Asset
Type: Common Stock
CIK:0001359931
Company Profile
Protara is committed to identifying and advancing transformative therapies for people with cancer and rare diseases with limited treatment options. Protara's portfolio includes its lead program, TARA-002, an investigational cell-based therapy being developed for the treatment of non-muscle invasive bladder cancer and lymphatic malformations, and IV Choline Chloride, an investigational phospholipid substrate replacement therapy for the treatment of intestinal failure-associated liver disease.
Sector: Manufacturing
Industry: Biological Product (except Diagnostic) Manufacturing
Standard Industrial Classification Code (SIC code): 2836
Address: 1 Little West 12Th Street
Website: protaratx.com
CEO: Jesse Shefferman
Tags:
- Health Technology
- Biotechnology
- Pharmaceuticals: Major
- Manufacturing
- Biological Product (except Diagnostic) Manufacturing
Pricing
Last Updated: October 3, 2023 03:00 PM EST
Previous Close: $1.59
Change:
-$0.09
(
-5.36%)
Days Range: $1.50 - $1.68
Beta: 1.08
52wk. High: $4.18
52wk. Low: $1.50
Ytd. Change -42.67%
50 Day Moving Average: $1.82
200 Day Moving Average: $2.52
Shares Outstanding: 11329080
Valuation
Market Cap: 1.8B
PE Ratio: -
EPS (TTM): 0
Dividends
Dividend Per Share (TTM): -
Dividend Yield (TTM): 0.00%
Ex-Dividend Date: N/A